Does weight return four times faster after stopping Ozempic?

What did @dw_espanol actually say?

The video, captioned in Spanish, claims weight returns "four times faster" after stopping GLP-1 medications like Ozempic compared to traditional dieting. The researcher in the clip, whose affiliation is garbled in transcription but appears to be a legitimate obesity scientist, says people "regain the weight faster" after stopping GLP-1 drugs and explains this is partly because the medication "does a lot of that work for you" on appetite suppression. The core argument is that patients don't learn to control appetite independently, leaving them vulnerable when they stop treatment.

The "four times faster" figure is specific and alarming enough to warrant scrutiny. The scientist in the clip does not actually say "four times faster" herself. That framing appears to come from the video's caption, not the researcher's words. That distinction matters.

Does the science back this up?

Partially, yes. Weight regain after stopping GLP-1 medications is real and well-documented. But the "four times faster" framing is not clearly supported by clinical trial data.

The most cited evidence comes from the STEP 1 trial extension (Wilding et al., 2022, Diabetes, Obesity and Metabolism), which followed participants who stopped semaglutide after 68 weeks of treatment. Within one year of stopping, participants regained approximately two-thirds of their lost weight. That is significant rebound. However, comparing that rate directly to "traditional diet" rebound requires a controlled head-to-head study, and no widely cited trial has produced a clean "four times faster" figure. The specific multiplier looks like an extrapolation, or possibly a misread of data.

What the research does consistently show is that GLP-1 drugs treat a biological condition, not a behavior problem. When the drug stops, the underlying physiology, including reduced satiety signaling, returns. That part of the video's message is scientifically grounded.

What did they get wrong (or right)?

The researcher gets the mechanism right. GLP-1 receptor agonists suppress appetite pharmacologically, meaning the drug handles much of the work a person would otherwise need behavioral strategies to manage. When you stop taking the drug, you lose that suppression. That is not controversial.

Where the video oversimplifies is in suggesting this is a flaw unique to GLP-1 drugs. Weight regain is the rule, not the exception, after stopping almost any effective obesity intervention, including low-calorie diets, bariatric surgery (to a lesser degree), and older anti-obesity medications. A 2020 review by Kraschnewski et al. in International Journal of Obesity found most dietary intervention participants regain significant weight within three to five years. The framing that GLP-1 drugs are distinctly bad here is misleading.

The claim that patients "don't learn to control appetite" also flattens a more complex picture. Some clinical programs pair GLP-1 treatment with behavioral counseling precisely to build those skills. Whether patients retain them after stopping is an open research question, not a settled failure.

What should you actually know?

GLP-1 medications like semaglutide appear to work best when treated as long-term or ongoing therapy, not a short course you stop after hitting a goal weight. The biology here matters: obesity involves dysregulated hormonal signaling, and GLP-1 drugs partially correct that. Stopping them does not fix the underlying condition, it just removes the correction.

The 2022 STEP 1 extension data and the SURMOUNT-4 trial data on tirzepatide (Aronne et al., 2024, JAMA) both show that continued use maintains weight loss, while discontinuation leads to substantial regain. This is not a scandal. It is how chronic disease medication works, similar to antihypertensives or statins.

Patients considering stopping GLP-1 therapy should discuss it with a prescriber, not base that decision on a TikTok caption. The "four times faster" figure specifically should be treated as unverified until a direct comparative study confirms it.